In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roivant Is Striving Towards New Standards Of Care

With numerous highly anticipated data readouts due over 2023, the spotlight is on Roivant like never before. CEO Matt Gline enlightens In Vivo on the firm’s ‘vant’ subsidiaries, its in-house drug development strategies and the future of its Vtama psoriasis treatment.

Companies Business Strategies Launches

The Mandate To Make A Digital Difference

Diogo Rau, chief information and digital officer at Lilly, talks to In Vivo about the company’s plans for making big and disruptive changes using digital strategy to speed up drug development.

Digital Health Safety Leadership

Putting The Patient First: The Challenge And Opportunities To Improve Rare-Disease Therapy Development


Advances in identifying the genetic causes of diseases, and particularly cancers, coupled with regulatory incentives to encourage the development of therapeutic approaches to once poorly managed orphan diseases have fueled a surge in exciting new medicines. To address some of these issues and explore potential solutions, Simbec-Orion in collaboration with Informa Pharma Intelligence convened a round table of experts attending the BIO International Convention

Read More

Growth Explore this Topic

Set Alert for Growth

Latest From Growth

Deals In 2023: Partnerships And Modest M&A

Mid-sized M&A, collaborations, creative financing, and biotech consolidation will feature in 2023. IPOs and follow-ons play bit-parts.

Growth Deals

Standalone Sandoz And Biocon’s Biosimilars: 2022’s Biggest Deals

The acquisition and consolidation mania that gripped industry in the middle half of the last decade may seem like a distant dream but players continued to spend cash where it could be justified in 2022, while raising much-needed capital to fund their endeavors.

M & A Deals

Slew Of Challenges Calls For Revised Biopharma Playbook

While not immune to the impact of a storm of macroeconomic pressures, pharma companies have pulled through before, and they’ll do it again. However, this time around, the economic, geopolitical and internal cost and revenue pressures are unique and weathering the near-term turbulence will call for smart investment strategies that not only focus on quality assets, but that update companies to take advantage of new digital opportunities.

Business Strategies Growth

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

Nimbus CEO Talks $4bn Takeda Deal And Capital Cycles

In December 2022, Nimbus Inc. completed one of the largest single-asset deals in the history of biotech, selling their TYK2 inhibitor program NDI-034858 for an up-front payment of $4bn and up to $2bn in additional milestone payments. What was it like to close a deal of that magnitude? What’s next for Nimbus? The company‘s CEO, Jeb Keiper, reflected on these questions in a recent interview with In Vivo.

Deals Exec Chats

Instead Of VC, Try Philanthropy: Inside Medical Research Charity LifeArc

In Vivo reporter Chloe Kent caught up with Life Arc CEO Melanie Lee to discuss the power of philanthropy in early-stage biopharma funding.

Financing Innovation

Industry Polarized In Best Manufacturing Approach For Cell And Gene Therapy

Ongoing debate emanates from industry players around the most efficient design of the manufacturing process for cell and gene therapies. The arguments surrounding outsourcing, centralizing, and standardizing processes will no doubt continue through into the near future.

Manufacturing Gene Therapy
Data Spotlight

Financing Quarterly Statistics, Q2 2022

During Q2, biopharmas brought in an aggregate $12.5bn in financing and device company fundraising totaled $3.7bn; while in vitro diagnostic firms and research tools players raised $720m.

Pandemic Windfall Upends Status Quo For Top-10 Best-Selling Drugs

This article reveals the top 10 pharmaceutical products by revenues in 2022 and discusses the major themes affecting the highest-grossing drugs and the companies behind their continued development.

Titans Of Pharma 2022: Johnson & Johnson Pays Highest Exec Compensation Again

Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

Nimbus CEO Talks $4bn Takeda Deal And Capital Cycles

In December 2022, Nimbus Inc. completed one of the largest single-asset deals in the history of biotech, selling their TYK2 inhibitor program NDI-034858 for an up-front payment of $4bn and up to $2bn in additional milestone payments. What was it like to close a deal of that magnitude? What’s next for Nimbus? The company‘s CEO, Jeb Keiper, reflected on these questions in a recent interview with In Vivo.

Deals Exec Chats

Execs On The Move: January 2023

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.  

Executive Changes Commercial

Panthera On The SMO Model, Responsible Growth Priorities And The Hybridized Trial Of The Future

In this episode of the In Vivo podcast, Jo Shorthouse speaks with the co-founder and chief commercial officer of the site management organization, Panthera Biopartners. The discussion centers on the practicalities and reality of running clinical trial sites as a business, and the age-old challenge of patient recruitment.

Clinical Trials Research & Development

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

How To Master The New Legal Responsibilities Introduced By The CTR

The Clinical Trials Regulation finally entered into application on 31 January 2022, replacing the largely national, and sometimes inconsistent, rules created by the Clinical Trials Directive. In this article, law firm Cooley advises on the changes introduced by the CTR and explores ways in which firms can reduce their contractual risks and potential legal liability.

Clinical Trials Regulation

The Serious Business Of Digital Medical Games

There are fewer than a handful of approved prescription video game digital therapeutics, but gamification in patient care is proving its worth as a novel way of treating a range of conditions, from vision loss to dyslexia and ADHD. Now, the onus is on lawmakers and insurers to create a clear path towards reimbursement.

Behavioral Health Digital Health

Worldwide Regulators Warm Up To Medical Marijuana

Both the US and EU are gradually warming up to medical marijuana, but clunky and inadequate regulation threatens to curtail the growth of a burgeoning industry.

Cannabidiol CBD Regulation

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

Deals In 2023: Partnerships And Modest M&A

Mid-sized M&A, collaborations, creative financing, and biotech consolidation will feature in 2023. IPOs and follow-ons play bit-parts.

Growth Deals

Standalone Sandoz And Biocon’s Biosimilars: 2022’s Biggest Deals

The acquisition and consolidation mania that gripped industry in the middle half of the last decade may seem like a distant dream but players continued to spend cash where it could be justified in 2022, while raising much-needed capital to fund their endeavors.

M & A Deals

New Deals, Modalities In Sights In Japan After Relatively Quiet 2022

After a comparatively subdued 2022 in terms of M&A and other deal-making, a strengthening currency and interest in new areas such as digital tools and cell and gene therapy might see a rebound in activity this year, which should also see domestic approvals of several potential blockbusters and more support for bioventures.

Japan Business Strategies
UsernamePublicRestriction

Register